Vimarsana
Biggest News Aggregation in the World

Page 36 - Ace2 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ace2. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ace2 Today - Breaking & Trending Today

Mucosal delivery of IFNs a good strategy for COVID-19 prophylaxis post-exposure - Vimarsana News

Mucosal delivery of IFNs a good strategy for COVID-19 prophylaxis post-exposure

Researchers from the UK and Germany recently reported a comprehensive characterization of the SARS-CoV-2 response of human nasal epithelial cells, revealing a response dominated by IFN-I/IIIs. Also, recombinant IFN-I/III treatment was found to efficiently block the replication of SARS-CoV-2, which suggests that mucosal delivery of IFNs may be a good strategy for prophylaxis post-exposure.

Polyphenols may provide protective effect against COVID-19 disease - Vimarsana News

Polyphenols may provide protective effect against COVID-19 disease

In the study published in the journal Integrative Physiology, the researchers found that a high intake of polyphenols may have a protective effect on patients with COVID-19 and prevent disease progression.

COVID-19 vaccine candidate shows potential against SARS-CoV-2 and potential future zoonotic coronaviruses - Vimarsana News

COVID-19 vaccine candidate shows potential against SARS-CoV-2 and potential future zoonotic coronaviruses

A new study sheds light on the threat posed by future zoonotic coronaviruses to make similar leaps across species barriers to infect human beings and cause other pandemics.

Researchers test the therapeutic efficacy of potential COVID-19 interventions in mouse models - Vimarsana News

Researchers test the therapeutic efficacy of potential COVID-19 interventions in mouse models

Researchers test the therapeutic efficacy of potential COVID-19 interventions in mouse models Aarthi Narayanan, Associate Professor, and Lance Liotta, Co-Director, Center for Applied Proteomics and Molecular Medicine (CAPMM), are conducting three studies to assess the therapeutic efficacy of candidate interventions for COVID-19 in mouse models. For the first study, the researchers hope to determine the survival advantage conferred by a therapeutic. Related Stories For this study, the researchers are infecting ACE2 animals intranasally with SARS-CoV-2 and following them for up to seven days af...

O-glycosylation of SARS-CoV-2 spike protein in insect and human cell lines - Vimarsana News

O-glycosylation of SARS-CoV-2 spike protein in insect and human cell lines

O-glycosylation of SARS-CoV-2 spike protein in insect and human cell lines Sites of O-glycosylation on the spike protein were near N-glycosites, suggesting O-glycans complement N-glycans' effect in immune shielding. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of the COVID-19 pandemic, has some characteristics that were not seen before in human coronaviruses, such as mutation on the receptor-binding domain (RBD) for high affinity to the human angiotensin-converting enzyme 2 (ACE2) and presence of a furin cleavage site between the two subunits of the spike protei...